-
公开(公告)号：US08580936B2
公开(公告)日：2013-11-12
申请号：US13227398
申请日：2011-09-07
申请人： Lewis T. Williams , Elizabeth Bosch , Stephen Doberstein , Kevin Hestir , Diane Hollenbaugh , Ernestine Lee , Minmin Qin , Ali Sadra , Justin Wong , Ge Wu , Hongbing Zhang
发明人： Lewis T. Williams , Elizabeth Bosch , Stephen Doberstein , Kevin Hestir , Diane Hollenbaugh , Ernestine Lee , Minmin Qin , Ali Sadra , Justin Wong , Ge Wu , Hongbing Zhang
CPC分类号： C07K14/71 , A61K45/06 , C07K14/765 , C07K16/2863 , C07K17/08 , C07K2319/30 , C07K2319/32
摘要： The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
摘要翻译： 本发明提供了FGFR融合蛋白，其制备方法以及使用它们来治疗增殖性疾病（包括癌症和血管生成障碍）的方法。 FGFR融合分子可以在CHO细胞中制备，并且可以包含改善其稳定性的FGFRs的细胞外结构域中的缺失突变。 这些融合蛋白体外和体内抑制癌细胞的生长和活力。 这些受体对其配体FGF的相对高亲和力的组合以及这些诱饵受体抑制肿瘤生长的证明的能力是本文提供的组合物和方法的临床价值的指示。
-
公开(公告)号：US07982014B2
公开(公告)日：2011-07-19
申请号：US12652720
申请日：2010-01-05
申请人： Lewis T. Williams , Elizabeth Bosch , Stephen Doberstein , Kevin Hestir , Diane Hollenbaugh , Ernestine Lee , Minmin Qin , Ali Sadra , Justin Wong , Ge Wu , Hongbing Zhang
发明人： Lewis T. Williams , Elizabeth Bosch , Stephen Doberstein , Kevin Hestir , Diane Hollenbaugh , Ernestine Lee , Minmin Qin , Ali Sadra , Justin Wong , Ge Wu , Hongbing Zhang
CPC分类号： C07K14/71 , A61K45/06 , C07K14/765 , C07K16/2863 , C07K17/08 , C07K2319/30 , C07K2319/32
摘要： The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
摘要翻译： 本发明提供了FGFR融合蛋白，其制备方法以及使用它们来治疗增殖性疾病（包括癌症和血管生成障碍）的方法。 FGFR融合分子可以在CHO细胞中制备，并且可以包含改善其稳定性的FGFRs的细胞外结构域中的缺失突变。 这些融合蛋白体外和体内抑制癌细胞的生长和活力。 这些受体对其配体FGF的相对高亲和力的组合以及这些诱饵受体抑制肿瘤生长的证明的能力是本文提供的组合物和方法的临床价值的指示。
-
公开(公告)号：US20070264277A1
公开(公告)日：2007-11-15
申请号：US11632319
申请日：2005-07-21
申请人： Dirk Behrens , Elizabeth Bosch , Stephen Doberstein , Robert Halenbeck , Kevin Hestir , Min Huang , Ernestine Lee , Haishan Lin , Thomas Linnemann , Shannon Marshall , Justin Wong , Ge Wu , Aileen Zhou
发明人： Dirk Behrens , Elizabeth Bosch , Stephen Doberstein , Robert Halenbeck , Kevin Hestir , Min Huang , Ernestine Lee , Haishan Lin , Thomas Linnemann , Shannon Marshall , Justin Wong , Ge Wu , Aileen Zhou
IPC分类号： A61K39/00 , A61K38/00 , C07H21/00 , C07K14/00 , C07K16/18 , C12N15/00 , C12N15/87 , C12N5/06 , C12P1/00 , G01N33/53
CPC分类号： C07K16/243 , A61K38/00 , C07K14/53
摘要： Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.
摘要翻译： 公开了一种新鉴定的分泌型分子，本文称为“单核细胞，粒细胞和树突细胞集落刺激因子”（MGD-CSF），多肽序列和编码多肽序列的多核苷酸。 还提供了通过使用例如载体和宿主细胞的重组技术产生多肽的方法。 另外，描述了修饰所公开的本发明新颖分子以制备融合分子的方法。 还公开了将多肽及其活性片段用于治疗各种疾病（包括例如癌症，自身免疫性和炎性疾病，感染性疾病和复发性妊娠损失）的方法。
-
公开(公告)号：US20130065276A1
公开(公告)日：2013-03-14
申请号：US13227398
申请日：2011-09-07
申请人： Lewis T. WILLIAMS , Elizabeth Bosch , Stephen Doberstein , Kevin Hestir , Diane Hollenbaugh , Ernestine Lee , Minmin Qin , Ali Sadra , Justin Wong , Ge Wu , Hongbing Zhang
发明人： Lewis T. WILLIAMS , Elizabeth Bosch , Stephen Doberstein , Kevin Hestir , Diane Hollenbaugh , Ernestine Lee , Minmin Qin , Ali Sadra , Justin Wong , Ge Wu , Hongbing Zhang
CPC分类号： C07K14/71 , A61K45/06 , C07K14/765 , C07K16/2863 , C07K17/08 , C07K2319/30 , C07K2319/32
摘要： The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
-
5.发明申请公开(公告)号：US20110281302A1
公开(公告)日：2011-11-17
申请号：US13157712
申请日：2011-06-10
申请人： Lewis T. WILLIAMS , Elizabeth Bosch , Stephen Doberstein , Kevin Hestir , Diane Hollenbaugh , Ernestine Lee , Minmin Qin , Ali Sadra , Justin Wong , Ge Wu , Hongbing Zhang
发明人： Lewis T. WILLIAMS , Elizabeth Bosch , Stephen Doberstein , Kevin Hestir , Diane Hollenbaugh , Ernestine Lee , Minmin Qin , Ali Sadra , Justin Wong , Ge Wu , Hongbing Zhang
CPC分类号： C07K14/71 , A61K45/06 , C07K14/765 , C07K16/2863 , C07K17/08 , C07K2319/30 , C07K2319/32
摘要： The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
摘要翻译： 本发明提供了FGFR融合蛋白，其制备方法以及使用它们来治疗增殖性疾病（包括癌症和血管生成障碍）的方法。 FGFR融合分子可以在CHO细胞中制备，并且可以包含改善其稳定性的FGFRs的细胞外结构域中的缺失突变。 这些融合蛋白体外和体内抑制癌细胞的生长和活力。 这些受体对其配体FGF的相对高亲和力的组合以及这些诱饵受体抑制肿瘤生长的证明的能力是本文提供的组合物和方法的临床价值的指示。
-
6.发明申请LRRTM1 Compositions and Methods of Their Use for the Diagnosis and Treatment of Cancer 审中-公开LRRTM1其用于诊断和治疗癌症的组合物和方法公开(公告)号：US20100028867A1
公开(公告)日：2010-02-04
申请号：US12084172
申请日：2006-10-25
申请人： Elizabeth Bosch , Kevin Hestir , Justin Wong
发明人： Elizabeth Bosch , Kevin Hestir , Justin Wong
IPC分类号： C12Q1/68 , G01N33/574
CPC分类号： C07K14/705 , A61K38/00
摘要： Microarray analysis, confirmed by RT-PCR, demonstrated that mRNA from certain cancer tissues, for example, ovarian cancer tissue, pancreatic cancer tissue, and colorectal cancer tissue, hybridizes specifically and preferentially to LRRTM1. LRRTM1 is a leucine-rich repeat transmembrane protein overexpressed on the surface of cancer cells compared to normal tissues and thus provides a therapeutic target for treating cancer. Modulators of LRRTM1, highly expressed in cancerous as compared to normal tissues, are provided for the diagnosis and treatment of proliferative disorders such as cancer. The invention further provides methods of treating cancer with therapeutic agents directed toward LRRTM1.
摘要翻译： 通过RT-PCR证实的微阵列分析表明，来自某些癌症组织例如卵巢癌组织，胰腺癌组织和结肠直肠癌组织的mRNA与LRRTM1具体和优先地杂交。 与正常组织相比，LRRTM1是在癌细胞表面上过表达的富含亮氨酸的重复跨膜蛋白，因此提供了治疗癌症的治疗靶点。 提供了与正常组织相比在癌症中高度表达的LRRTM1的调节剂用于诊断和治疗增殖性疾病如癌症。 本发明还提供了针对LRRTM1的治疗剂治疗癌症的方法。
-
7.发明申请公开(公告)号：US20120301921A1
公开(公告)日：2012-11-29
申请号：US13438638
申请日：2012-04-03
申请人： Lewis T. Williams , Elizabeth Bosch , Stephen Doberstein , Kevin Hestir , Diane Hollenbaugh , Ernestine Lee , Minmin Qin , Ali Sadra , Justin Wong , Ge Wu , Hongbing Zhang
发明人： Lewis T. Williams , Elizabeth Bosch , Stephen Doberstein , Kevin Hestir , Diane Hollenbaugh , Ernestine Lee , Minmin Qin , Ali Sadra , Justin Wong , Ge Wu , Hongbing Zhang
CPC分类号： C07K14/71 , A61K45/06 , C07K14/765 , C07K16/2863 , C07K17/08 , C07K2319/30 , C07K2319/32
摘要： The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
摘要翻译： 本发明提供了FGFR融合蛋白，其制备方法以及使用它们来治疗增殖性疾病（包括癌症和血管生成障碍）的方法。 FGFR融合分子可以在CHO细胞中制备，并且可以包含改善其稳定性的FGFRs的细胞外结构域中的缺失突变。 这些融合蛋白体外和体内抑制癌细胞的生长和活力。 这些受体对其配体FGF的相对高亲和力的组合以及这些诱饵受体抑制肿瘤生长的证明的能力是本文提供的组合物和方法的临床价值的指示。
-
8.发明申请公开(公告)号：US20080171689A1
公开(公告)日：2008-07-17
申请号：US11791889
申请日：2006-07-24
申请人： Lewis T. Williams , Elizabeth Bosch , Stephen Doberstein , Kevin Hestir , Diane Hollenbaugh , Ernestine Lee , Minmin Qin , Ali Sadra , Justin Wong , Ge Wu , Hongbing Zhang
发明人： Lewis T. Williams , Elizabeth Bosch , Stephen Doberstein , Kevin Hestir , Diane Hollenbaugh , Ernestine Lee , Minmin Qin , Ali Sadra , Justin Wong , Ge Wu , Hongbing Zhang
CPC分类号： C07K14/71 , A61K45/06 , C07K14/765 , C07K16/2863 , C07K17/08 , C07K2319/30 , C07K2319/32
摘要： The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
摘要翻译： 本发明提供了FGFR融合蛋白，其制备方法以及使用它们来治疗增殖性疾病（包括癌症和血管生成障碍）的方法。 FGFR融合分子可以在CHO细胞中制备，并且可以包含改善其稳定性的FGFRs的细胞外结构域中的缺失突变。 这些融合蛋白体外和体内抑制癌细胞的生长和活力。 这些受体对其配体FGF的相对高亲和力的组合以及这些诱饵受体抑制肿瘤生长的证明的能力是本文提供的组合物和方法的临床价值的指示。
-
9.发明申请公开(公告)号：US20100158911A1
公开(公告)日：2010-06-24
申请号：US12652720
申请日：2010-01-05
申请人： Lewis T. Williams , Elizabeth Bosch , Stephen Doberstein , Kevin Hestir , Diane Hollenbaugh , Ernestine Lee , Minmin Qin , Ali Sadra , Justin Wong , Ge Wu , Hongbing Zhang
发明人： Lewis T. Williams , Elizabeth Bosch , Stephen Doberstein , Kevin Hestir , Diane Hollenbaugh , Ernestine Lee , Minmin Qin , Ali Sadra , Justin Wong , Ge Wu , Hongbing Zhang
IPC分类号： A61K39/395 , C07K19/00 , C07K14/00 , C07H21/04 , A61K38/16 , A61P35/00 , A61P35/04 , C12N5/10 , C12P21/06 , C12N15/63 , G01N33/53
CPC分类号： C07K14/71 , A61K45/06 , C07K14/765 , C07K16/2863 , C07K17/08 , C07K2319/30 , C07K2319/32
摘要： The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.
摘要翻译： 本发明提供了FGFR融合蛋白，其制备方法以及使用它们来治疗增殖性疾病（包括癌症和血管生成障碍）的方法。 FGFR融合分子可以在CHO细胞中制备，并且可以包含改善其稳定性的FGFRs的细胞外结构域中的缺失突变。 这些融合蛋白体外和体内抑制癌细胞的生长和活力。 这些受体对其配体FGF的相对高亲和力的组合以及这些诱饵受体抑制肿瘤生长的证明的能力是本文提供的组合物和方法的临床价值的指示。
-
公开(公告)号：US20110003384A1
公开(公告)日：2011-01-06
申请号：US12370559
申请日：2009-02-12
申请人： Dirk BEHRENS , Elizabeth Bosch , Stephen K. Doberstein , Robert Forgan Halenbeck , Kevin Hestir , Min Mei Huang , Ernestine Lee , Haishan Lin , Thomas Linnemann , Shannon Marshall , Justin G. P. Wong , Ge Wu , Aileen Zhou , Cindy Leo , Lewis T. Williams
发明人： Dirk BEHRENS , Elizabeth Bosch , Stephen K. Doberstein , Robert Forgan Halenbeck , Kevin Hestir , Min Mei Huang , Ernestine Lee , Haishan Lin , Thomas Linnemann , Shannon Marshall , Justin G. P. Wong , Ge Wu , Aileen Zhou , Cindy Leo , Lewis T. Williams
IPC分类号： C12N5/071
CPC分类号： C07K16/243 , A61K38/00 , C07K14/53
摘要： Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.
摘要翻译： 公开了一种新鉴定的分泌型分子，本文称为“单核细胞，粒细胞和树突细胞集落刺激因子”（MGD-CSF），多肽序列和编码多肽序列的多核苷酸。 还提供了通过使用例如载体和宿主细胞的重组技术产生多肽的方法。 另外，描述了修饰所公开的本发明新颖分子以制备融合分子的方法。 还公开了将多肽及其活性片段用于治疗各种疾病（包括例如癌症，自身免疫性和炎性疾病，感染性疾病和复发性妊娠损失）的方法。
-
-
-
-
-
-
-
-
-
搜索结果
19 条记录 (耗时 0.035 秒)
